Linda Hiraki, MD, ScD, Seeks Advocacy, Collaborations via the Committee on Research

Linda Hiraki, MD, ScD, with the Division of Rheumatology, The Hospital for Sick Children (SickKids) in Toronto, has volunteered with the ACR Special Committee on Pediatrics, the Annual Meeting Planning Committee and as co-chair of the ACR/CARRA Mentoring Interest Group for pediatric rheumatologists. Dr. Hiraki tells The Rheumatologist what she plans to do as chair of the Committee on Research (COR), which she’s served as a member of since 2021, and shares what makes ACR committee volunteerism so rewarding.

The Rheumatologist (TR): Could you explain what the COR does?

Dr. Hiraki

Dr. Hiraki: The COR is a joint ACR/ARP committee. The COR encourages basic, clinical and health services research on a range of topics impacting patients with rheumatic diseases. It executes this overarching goal through advocacy, dissemination and interprofessional collaboration. The COR works closely with the Rheumatology Research Foundation to coordinate and align these efforts. COR members are liaisons on other ACR committees, such as the Government Affairs Committee for legislative advocacy and the Annual Meeting Planning Committee. In these many-faceted ways, the COR works to advance research for ACR members and patients with rheumatic diseases.

TR: What prompted your interest in becoming chair of the COR?

Dr. Hiraki: Over the years, I have had the honor of serving on different ACR committees. These experiences provided me opportunities and insights into how committee work may benefit our broader rheumatology community. I joined the COR in 2021 under the leadership of Kristi Kuhn, MD, PhD. As part of the committee, I co-organized the Basic and Clinical Research Conference and helped write the five-year NIH grant supporting the conference. As a clinician-scientist committed to advancing research, I appreciated the broad, multifaceted impact of the COR. The COR chair position is an opportunity to continue and also build on this work with an outstanding group of ACR and ARP members who are dedicated and passionate about advocating for scholarly research for the benefit of our patients. 

TR: Could you say a little about the research advocacy components that outgoing chair Dr. Kuhn worked on with the ACR advocacy team, such as getting an arthritis research line item in the Department of Defense (DOD) budget? Why is this work significant?

Dr. Hiraki: Research funding support has become more limited and competitive in recent years, making it imperative for our community to ensure that funds are dedicated to support essential rheumatology research. Dr. Kuhn worked for 10 years to obtain a line item for arthritis research in the DOD budget. Arthritis is the second leading cause of medical discharge from the military (the first being traumatic brain injury). Yet, until this last year, dedicated funding to understand the etiology of arthritis and identify effective treatments was absent. This line item was a huge win for the COR and the Government Affairs Committee. Moving forward, we are actively involved in the 2025–2029 National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) Strategic Planning process and are exploring ways that we can partner with NIAMS to benefit our membership.